2022
DOI: 10.1097/md.0000000000029245
|View full text |Cite
|
Sign up to set email alerts
|

Role of pilocarpine use following laser peripheral iridotomy in eyes with refractory acute angle closure glaucoma: A case report and literature review

Abstract: Rationale: Angle closure glaucoma (ACG) is one of the most emergent types of glaucoma in clinical practice. Laser peripheral iridotomy (LPI) could minimize pupillary block and prevent ACG from an acute attack. However, recurrent increase in intraocular pressure (IOP) may still occur despite successful LPI. The aim of this study is to highlight the importance of postLPI pilocarpine use and larger LPI size as well as to share some experiences of cataract surgery in patients with ACG. Patient concerns: A 63-yea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…Currently, various types of IOP-lowering antiglaucoma ophthalmic solutions are available [4,5]. These IOP-lowering antiglaucoma ophthalmic solutions were classified into eight categories: prostanoid receptor-related drugs [6], ß-blockers [7], carbonic anhydrase inhibitors [8], α2 adrenergic agonists [9], rho-kinase inhibitors [10], parasympathomimetic drugs [11],…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, various types of IOP-lowering antiglaucoma ophthalmic solutions are available [4,5]. These IOP-lowering antiglaucoma ophthalmic solutions were classified into eight categories: prostanoid receptor-related drugs [6], ß-blockers [7], carbonic anhydrase inhibitors [8], α2 adrenergic agonists [9], rho-kinase inhibitors [10], parasympathomimetic drugs [11],…”
Section: Introductionmentioning
confidence: 99%
“…Currently, various types of IOP-lowering antiglaucoma ophthalmic solutions are available [ 4 , 5 ]. These IOP-lowering antiglaucoma ophthalmic solutions were classified into eight categories: prostanoid receptor-related drugs [ 6 ], ß-blockers [ 7 ], carbonic anhydrase inhibitors [ 8 ], α2 adrenergic agonists [ 9 ], rho-kinase inhibitors [ 10 ], parasympathomimetic drugs [ 11 ], α1 blockers [ 12 ], and ion channel openers [ 13 , 14 ]. Among these categories, prostanoid receptor-related drug monotherapy is most commonly administered for the initial treatment of chronic open-angle glaucoma [ 15 ].…”
Section: Introductionmentioning
confidence: 99%